Early diagnostic protein biomarkers for breast cancer: how far have we come? Annemieke W. J. Opstal-van WindenRoel C. H. VermeulenCarla H. van Gils Review 17 December 2011 Pages: 1 - 12
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer Hope S. RugoA. Jo ChienMaura N. Dickler Review Open access 24 December 2011 Pages: 13 - 20
Molecular insights on basal-like breast cancer Mev Dominguez ValentinSabrina Daniela da SilvaYves-Jean Bignon Review 11 January 2012 Pages: 21 - 30
Fingolimod potentiates the effects of sunitinib malate in a rat breast cancer model Yoanne MousseauSéverine MollardFranck G. Sturtz Preclinical study 09 December 2011 Pages: 31 - 40
Integration of BRCA1-mediated miRNA and mRNA profiles reveals microRNA regulation of TRAF2 and NFκB pathway Miljana TanicMagdalena ZajacBeatriz Martínez-Delgado Preclinical study 14 December 2011 Pages: 41 - 51
A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines Edith BlackburnStefania ZonaWilliam J. Gullick Preclinical study 15 December 2011 Pages: 53 - 59
T cells sensitized with breast tumor progenitor cell vaccine have therapeutic activity against spontaneous HER2/neu tumors Li-Xin WangGregory E. Plautz Preclinical Study 16 December 2011 Pages: 61 - 70
Psoriasin (S100A7) increases the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferation Emman ShubbarJenny VegforsCharlotta Enerbäck Preclinical study 22 December 2011 Pages: 71 - 80
Biologically effective dose and breast cancer conservative treatment: is duration of radiation therapy really important? Pietro SanpaoloViviana BarbieriGiampiero Ausili Cèfaro Preclinical study 28 December 2011 Pages: 81 - 87
Antitumor effects of cytoplasmic delivery of an innate adjuvant receptor ligand, poly(I:C), on human breast cancer Touko InaoNanae HarashimaMamoru Harada Preclinical Study 28 December 2011 Pages: 89 - 100
SLC22A5/OCTN2 expression in breast cancer is induced by estrogen via a novel intronic estrogen-response element (ERE) Chunyu WangIvan P. UrayPowel H. Brown Preclinical Study 03 January 2012 Pages: 101 - 115
Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin Khalid Abu AjajRalph GraeserFelix Kratz Preclinical Study 08 January 2012 Pages: 117 - 129
Methylation of O 6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients Caterina FumagalliGiancarlo PruneriMassimo Barberis Preclinical Study 08 January 2012 Pages: 131 - 137
Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells Keiko KajitaniYuka TanakaHideki Ohdan Preclinical Study 20 January 2012 Pages: 139 - 155
Stromal–epithelial interactions modulate cross-talk between prolactin receptor and HER2/Neu in breast cancer Cong XuJohn F. LangenheimWen Y. Chen Preclinical study 22 January 2012 Pages: 157 - 169
Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients Xiangshan ZhaoSameer MirzaVimla Band Preclinical study Open access 22 January 2012 Pages: 171 - 180
Autologous microsurgical breast reconstruction and coronary artery bypass grafting: an anatomical study and clinical implications Warren M. RozenXuan YeIain S. Whitaker Preclinical Study 22 January 2012 Pages: 181 - 198
Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy Rainer GirgertGünter EmonsCarsten Gründker Preclinical Study Open access 31 January 2012 Pages: 199 - 205
The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer Karina H. GravgaardMaria B. LyngHenrik J. Ditzel Preclinical study 01 February 2012 Pages: 207 - 217
MUTYH gene variants and breast cancer in a Dutch case–control study Astrid A. OutMarijke WasielewskiPeter Devilee Preclinical Study Open access 02 February 2012 Pages: 219 - 227
14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers Yukiko NakamuraKazuteru OshimaShinzaburo Noguchi Preclinical Study 08 February 2012 Pages: 229 - 236
Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer Sebastian F. SchoppmannAnna BerghoffPeter Birner Preclinical study 17 February 2012 Pages: 237 - 244
Aromatase inhibitors and calcium absorption in early stage breast cancer Amye TevaarwerkMark E. BurkardKaren E. Hansen Preclinical Study 18 February 2012 Pages: 245 - 251
An abnormal screening mammogram causes more anxiety than a palpable lump in benign breast disease C. M. G. Keyzer-DekkerL. van EschA. F. W. van der Steeg Clinical trial Open access 21 March 2012 Pages: 253 - 258
The fibroblast growth factor receptor 1 (FGFR1), a marker of response to chemoradiotherapy in breast cancer? Carole MassabeauBrigitte Sigal-ZafraniAlain Fourquet Clinical Trial 22 March 2012 Pages: 259 - 266
Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study J. G. H. van NesD. B. Y. FonteinC. J. H. van de Velde Clinical trial Open access 28 March 2012 Pages: 267 - 276
Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer Elisabetta MunzoneE. BotteriG. Viale Clinical trial 01 April 2012 Pages: 277 - 282
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study Marta PestrinSilvia BessiAngelo Di Leo Clinical trial 04 April 2012 Pages: 283 - 289
High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study Adedayo A. OnitiloJessica M. EngelSuhail A. R. Doi Clinical Trial 04 April 2012 Pages: 291 - 298
Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene Trevor J. PowlesSusan J. DiemSteven R. Cummings Clinical Trial 08 April 2012 Pages: 299 - 306
A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients’ persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer Ke-Da YuYing ZhouZhen-Zhou Shen Clinical Trial 12 April 2012 Pages: 307 - 313
Predictors of functional shoulder recovery at 1 and 12 months after breast cancer surgery Ellen W. LevyLucinda A. PfalzerNicole L. Stout Clinical Trial 19 April 2012 Pages: 315 - 324
Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity M. ToulmondeN. MadrangesM. Debled Clinical Trial 25 April 2012 Pages: 325 - 332
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers Libero SantarpiaYuan QiLajos Pusztai Clinical Trial 27 April 2012 Pages: 333 - 343
A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103) Tianhong LiMengye GuoGeorge W. Sledge Clinical trial 01 May 2012 Pages: 345 - 352
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study Florentia FostiraMarianthi TsitlaidouGeorge Fountzilas Epidemiology 21 March 2012 Pages: 353 - 362
Breast cancer incidence trends in European women aged 20–39 years at diagnosis D. F. MerloM. CeppiAIRTUM WG Epidemiology 29 March 2012 Pages: 363 - 370
Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer A. H. KamalF. CamachoG. Kimmick Epidemiology 31 March 2012 Pages: 371 - 378
Quality of life over time in women diagnosed with ductal carcinoma in situ, early-stage invasive breast cancer, and age-matched controls D. B. JeffeM. PérezM. Schootman Epidemiology 08 April 2012 Pages: 379 - 391
Genetic polymorphisms in telomere pathway genes, telomere length, and breast cancer survival Jing ShenMarilie D. GammonRegina M. Santella Epidemiology 12 April 2012 Pages: 393 - 400
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel Daniel L. HertzAlison A. Motsinger-ReifE. Claire Dees Epidemiology 18 April 2012 Pages: 401 - 410
Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy Laura OttiniValentina SilvestriDomenico Palli Epidemiology 18 April 2012 Pages: 411 - 418
Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL) Alfred I. NeugutGrace Clarke HillyerDawn L. Hershman Epidemiology 22 April 2012 Pages: 419 - 428
Predisposition gene identification in common cancers by exome sequencing: insights from familial breast cancer Katie SnapeElise RuarkNazneen Rahman Brief Report 18 April 2012 Pages: 429 - 433
Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeat Laura CortesiArcangela De NicoloMassimo Federico Brief Report 22 April 2012 Pages: 435 - 441
Comments on the use of a single or multiple probeset approach for microarray-based analyses of routine molecular markers in breast cancer Frédérique SpyratosFabien ValetPatricia de Cremoux Letter to the Editor 12 April 2012 Pages: 443 - 448
Erratum to: Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents Gais KadraPascal FinettiAnthony Gonçalves Erratum 14 February 2012 Pages: 449 - 451